Market closed
Corvus Pharmaceuticals/$CRVS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Ticker
$CRVS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
28
Website
CRVS Metrics
BasicAdvanced
$598M
Market cap
-
P/E ratio
-$0.44
EPS
1.10
Beta
-
Dividend rate
Price and volume
Market cap
$598M
Beta
1.1
52-week high
$9.28
52-week low
$1.23
Average daily volume
847K
Financial strength
Current ratio
3.619
Quick ratio
3.552
Long term debt to equity
1.366
Total debt to equity
1.366
Management effectiveness
Return on assets (TTM)
-23.83%
Return on equity (TTM)
-44.91%
Valuation
Price to book
11.67
Price to tangible book (TTM)
11.67
Price to free cash flow (TTM)
-23.27
Growth
Earnings per share change (TTM)
-47.71%
3-year earnings per share growth (CAGR)
36.99%
What the Analysts think about CRVS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
CRVS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRVS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRVS News
AllArticlesVideos
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
Seeking Alpha·4 hours ago
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
GlobeNewsWire·4 days ago
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Corvus Pharmaceuticals stock?
Corvus Pharmaceuticals (CRVS) has a market cap of $598M as of November 13, 2024.
What is the P/E ratio for Corvus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of November 13, 2024.
Does Corvus Pharmaceuticals stock pay dividends?
No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of November 13, 2024.
When is the next Corvus Pharmaceuticals dividend payment date?
Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.